JPWO2022197900A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022197900A5 JPWO2022197900A5 JP2023556755A JP2023556755A JPWO2022197900A5 JP WO2022197900 A5 JPWO2022197900 A5 JP WO2022197900A5 JP 2023556755 A JP2023556755 A JP 2023556755A JP 2023556755 A JP2023556755 A JP 2023556755A JP WO2022197900 A5 JPWO2022197900 A5 JP WO2022197900A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pharmaceutical composition
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 11
- 230000001394 metastastic effect Effects 0.000 claims 9
- 206010061289 metastatic neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 238000003745 diagnosis Methods 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 6
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 4
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 230000000306 recurrent effect Effects 0.000 claims 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 3
- 229960005079 pemetrexed Drugs 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 102000025171 antigen binding proteins Human genes 0.000 claims 2
- 108091000831 antigen binding proteins Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000009093 first-line therapy Methods 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 230000002250 progressing effect Effects 0.000 claims 2
- 208000037821 progressive disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000009121 systemic therapy Methods 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 1
- BKKWZCSSYWYNDS-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2,6-diaminohexanoic acid Chemical group NCC(O)=O.NCCCC[C@H](N)C(O)=O BKKWZCSSYWYNDS-JEDNCBNOSA-N 0.000 claims 1
- 206010061819 Disease recurrence Diseases 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 206010061309 Neoplasm progression Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163779P | 2021-03-19 | 2021-03-19 | |
| US63/163,779 | 2021-03-19 | ||
| PCT/US2022/020714 WO2022197900A1 (en) | 2021-03-19 | 2022-03-17 | Methods for treating cancer with anti-ilt3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511977A JP2024511977A (ja) | 2024-03-18 |
| JPWO2022197900A5 true JPWO2022197900A5 (enrdf_load_stackoverflow) | 2025-03-24 |
Family
ID=83320983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556755A Pending JP2024511977A (ja) | 2021-03-19 | 2022-03-17 | 抗ｉｌｔ３抗体によるがんの治療方法 |
Country Status (10)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102478433B1 (ko) * | 2017-11-17 | 2022-12-15 | 머크 샤프 앤드 돔 엘엘씨 | 이뮤노글로불린-유사 전사체 3 (ilt3)에 대해 특이적인 항체 및 그의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117205313A (zh) * | 2017-01-20 | 2023-12-12 | 埃克塞里艾克西斯公司 | 治疗癌症的卡博替尼与阿特珠单抗组合 |
| KR102478433B1 (ko) * | 2017-11-17 | 2022-12-15 | 머크 샤프 앤드 돔 엘엘씨 | 이뮤노글로불린-유사 전사체 3 (ilt3)에 대해 특이적인 항체 및 그의 용도 |
| US20220177534A1 (en) * | 2018-05-10 | 2022-06-09 | The Regents Of The University Of California | Ccl21 and checkpoint inhibitors for the treatment of cancer |
-
2022
- 2022-03-17 CA CA3212604A patent/CA3212604A1/en active Pending
- 2022-03-17 WO PCT/US2022/020714 patent/WO2022197900A1/en active Application Filing
- 2022-03-17 EP EP22772190.9A patent/EP4308243A4/en active Pending
- 2022-03-17 JP JP2023556755A patent/JP2024511977A/ja active Pending
- 2022-03-17 CN CN202280036448.1A patent/CN117412771A/zh active Pending
- 2022-03-17 KR KR1020237035228A patent/KR20230158057A/ko active Pending
- 2022-03-17 MX MX2023010825A patent/MX2023010825A/es unknown
- 2022-03-17 BR BR112023018921A patent/BR112023018921A2/pt unknown
- 2022-03-17 US US18/550,537 patent/US20240317854A1/en active Pending
- 2022-03-17 AU AU2022239502A patent/AU2022239502A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| US20190160148A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| Nam et al. | Safety and tolerability of weekly Genexol-PM, a Cremophor-Free polymeric micelle formulation of paclitaxel, with carboplatin in gynecologic cancer: A phase I study | |
| US20210260064A1 (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
| CN113840608B (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2017515843A (ja) | 抗ｅｇｆｒ治療薬の投与量および投与 | |
| JPWO2020030977A5 (enrdf_load_stackoverflow) | ||
| JPWO2022197900A5 (enrdf_load_stackoverflow) | ||
| EP4384166A1 (en) | Oral composition comprising a mdm2-antagonist for cancer therapy | |
| US20250049940A1 (en) | Combined Use of Anti-TROP-2 Antibody-drug Conjugate and other Therapeutic Agents | |
| Naqash et al. | 720TiP Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations | |
| WO2019070497A1 (en) | POLY THERAPY AGAINST CANCER | |
| US20240335464A1 (en) | Administration of sting agonist, checkpoint inhibitors, and radiation | |
| US20230085602A1 (en) | Pdac treatment regimen | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| Garrido López et al. | Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC | |
| CN118924750A (zh) | 吡啶胺化合物在经克唑替尼治疗后耐药的非小细胞肺癌中的应用 | |
| CN116490244A (zh) | Sting激动剂、检查点抑制剂和辐射的施用 | |
| CN111821304A (zh) | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途 | |
| Reddy et al. | 2004 Highlights From: The 27th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2004 |